Pharmicell Reports 56.2 Billion KRW in Sales and 3.7 Billion KRW in Net Profit Last Year

On the 13th, Pharmicell announced that its sales revenue last year amounted to 56.2 billion KRW, operating profit was 1.2 billion KRW, and net income was 3.7 billion KRW.

The Biochemical Division, which produces raw materials for gene therapy drugs, recorded sales of 54.6 billion KRW, a 7% decrease compared to the previous year, while the Biomedical Division, which produces stem cell therapies, posted sales of 1.6 billion KRW.

By product category, raw pharmaceutical materials such as nucleosides and mPEG accounted for 23.5 billion KRW, and the advanced materials sector recorded 29.5 billion KRW. Sales of mPEG, the raw material for UCB Pharma's Cimzia, increased by 83% from the previous year to 8.8 billion KRW. Shipment volumes continue to rise.

A Pharmicell representative explained, "Although the nucleoside segment's performance has been sluggish due to the COVID-19 endemic, the global nucleoside market is expected to grow with the increase in mRNA therapeutic clinical trials." He added, "This year, we anticipate sales growth by expanding the production capacity of the high-margin product mPEG."

He also stated, "Recently, new demand has surged in the advanced materials sector, including AI-related low dielectric materials and optical materials, which will drive Pharmicell's growth."

Furthermore, he added, "With the recent amendment to the Advanced Regenerative Bio Act allowing treatment after clinical research in advanced regenerative medicine, the Biomedical Division's stem cell therapy-related business is expected to gain momentum."

This content was produced with the assistance of AI translation services.